Clinical AI Assurance Attestation

Defining Clinical AI Assurance Attestation

A clinical AI assurance attestation is not a single certificate or form. It is a structured set of technical, safety, and governance claims that a healthcare organization or AI vendor substantiates with documented evidence. Rather than pointing to one regulatory instrument, these attestations draw on overlapping frameworks that each cover a different scope: device-level oversight from the FDA, transparency requirements for predictive decision support tools from HHS/ONC, organizational risk management practices from NIST, and AI management system requirements from ISO/IEC 42001.

An attestation claim typically asserts that a clinical AI system has been validated against defined performance criteria, that its intended use and limitations are documented, that risk management practices are in place, and that human oversight mechanisms exist to catch errors before they affect patient care. Treating attestation as a composite of requirements, rather than a single deliverable, is the starting point for determining what evidence an organization actually needs to produce and maintain.

What a Clinical AI Attestation Must Cover

Across the frameworks above, attestation evidence generally falls into a small number of recurring categories. Mapping claims to these categories helps teams avoid treating attestation as one static packet of documents.

Evidence Requirements

Organizations preparing attestation support typically need documented artifacts in each of the following areas:

• Validation evidence: performance data, testing methodology, and intended use documentation establishing that a model performs as claimed for a specific clinical population and setting.
• Transparency documentation: source attributes such as training data descriptions, intended use statements, and validation methods, aligned with HTI-1 requirements for predictive decision support interventions.
• Risk management records: documented risk identification, mitigation, and monitoring practices, consistent with NIST AI RMF’s Map and Measure functions.
• Human oversight controls: defined points where clinicians can review, override, or escalate AI-generated recommendations before they affect care decisions.
• Change control documentation: a defined process for approving and recording model or policy modifications after deployment, similar in intent to FDA’s PCCP approach for adaptive algorithms.
• Audit trail evidence: logs of AI system behavior in production sufficient to reconstruct decisions during an internal review or regulatory inquiry.

Point-in-Time Validation Versus Continuous Assurance

Traditional compliance checkpoints validate a model once, before deployment, and treat that validation as sufficient until the next major review. Clinical AI systems, particularly adaptive models and AI agents that call tools or interact with EHR workflows, behave differently. Their outputs can drift as underlying data distributions shift, and agents may take actions beyond generating text, such as querying records or invoking external tools, that a static model card cannot describe.

HTI-1 reflects this by requiring ongoing risk management, not only pre-deployment validation, and FDA’s PCCP guidance exists specifically because regulators recognize that adaptive algorithms change after clearance. Supporting an attestation claim over time requires runtime monitoring that tracks live inference behavior for drift or policy violations, audit logging that records agent actions and tool calls to reconstruct decision provenance, and policy enforcement that can permit or block agent actions in line with defined human oversight controls.

Model versioning and change-control architecture is what distinguishes an approved modification from uncontrolled drift, giving reviewers a defensible record of what changed, when, and why. Runtime governance platforms, such as Trussed AI, that provide policy enforcement, audit logging, and agent identity and permission controls are built to generate this kind of continuous evidence, complementing rather than replacing point-in-time validation.

Producing and Maintaining Attestation Evidence

Responsibility for attestation evidence is typically shared between developers and deploying organizations. Model-level documentation often originates with the vendor; workflow-level risk management, oversight, and monitoring sit with the healthcare organization. Evidence should be refreshed whenever models or associated policies change, not only at initial release.

Is there a single official clinical AI assurance attestation standard?

No. Attestation claims typically draw on multiple frameworks, including FDA device oversight, HTI-1 transparency rules, NIST AI RMF, and ISO/IEC 42001, rather than one unified certification. Organizations should expect to map evidence against several sources depending on the specific AI system and its regulatory scope.

Who is responsible for producing attestation evidence, the vendor or the healthcare organization?

Responsibility is typically shared. AI developers generally produce model-level documentation such as validation data and source attributes, while deploying healthcare organizations are responsible for risk management, human oversight, and monitoring within their own clinical workflows.

How often should attestation evidence be updated?

Evidence should be updated whenever a model or its associated policies are modified, retrained, or reconfigured, not only at initial deployment. This reflects the ongoing risk management expectations described in HTI-1 and the iterative structure of NIST’s AI RMF.